Mouse anti Human CD13, conjugated with FITC
0132
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetANPEP
Overview
- SupplierNordic-MUbio
- Product NameMouse anti Human CD13, conjugated with FITC
- Delivery Days Customer7
- Application Supplier NotePBMC: Add10 microl of MAB/10^6 PBMC in 100 microl PBS. Mix gently and incubate for 15 minutes at 2 to 8C. Wash twice with PBS and analyze. WHOLE BLOOD: Add 10 microl of MAB/100 microl of whole blood. Mix gently and incubate for 15 minutes at room temperature (20C). Lyse the whole blood. Wash once with PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
- ApplicationsFlow Cytometry
- Applications SupplierFlow Cytometry
- Category SupplierPrimary antibodies
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDE735
- ConjugateFITC
- Gene ID290
- Target nameANPEP
- Target descriptionalanyl aminopeptidase, membrane
- Target synonymsalanyl (membrane) aminopeptidase; aminopeptidase M; aminopeptidase N; AP-M; APN; AP-N; CD13; GP150; hAPN; LAP1; membrane alanyl aminopeptidase; microsomal aminopeptidase; myeloid plasma membrane glycoprotein CD13; P150; PEPN
- HostMouse
- IsotypeIgG1
- Protein IDP15144
- Protein NameAminopeptidase N
- Scientific DescriptionCD13 FITC
- Shelf life instructionSee expiration date on vial
- ReactivityHuman
- Reactivity SupplierHuman
- Reactivity Supplier NoteCD13=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c x C57BL16 hybrid mice immunized with KG-1a cell line.
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- 1. Induction of CD13 expression on fresh myeloid leukemia: correlation of CD13 expression with aminopeptidase-N activity. Razak K; Newland AC Leuk Res 1992 Jun-Jul;16(6-7):625-30. 2. Surface marker expression in acute myeloid leukemia at first relapse. Thomas X; Campos L; Archimbaud E; Shi ZH; Treille-Ritouet D; Anglaret B; Fiere D Br J Haematol 1992 May;81(1):40-4. 3. Acute undifferentiated leukemia with CD7+ and CD13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Bassan R; Biondi A; Benvestito S; Tini ML; Abbate M; Viero P; Barbui T; Rambaldi A Cancer 1992 Jan 15;69(2):396-404. 4. Monocytes appearing repeatedly after chemotherapies had an identical rearrangement pattern of immunoglobulin with leukemic blasts in a patient with CD13+ acute lymphoblastic leukemia. Mizuki M; Tagawa S; Nojima J; Nakamura Y; Morita T; Yumura-Yagi K; Hara J; Kawa-Ha K; Kitani T Acta Haematol 1992;87(1-2):88-93.